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Background: Epidermal growth factor and v-Ki-ras2 Kirsten ras 
sarcoma (KRAS) mutation status, although associated with EGFR- 
tyrosine kinase inhibitor (TKI) efficacy, has not been used in clini-
cal practice until recently. The prospective Evaluation of the EGFR 
Mutation status for the administration of EGFR-TKIs in non small 
cell lung Carcinoma (ERMETIC) study aimed to implement these 
biomarkers in France.
Methods: Between March 2007 and April 2008, EGFR and KRAS 
were studied by sequencing DNA tumor specimens from 522 con-
secutive advanced non–small-cell lung cancer patients treated with 
EGFR-TKI, mostly in second- or third-line settings. Cox models 
were used to investigate the impact of patient characteristics and 
mutations on progression-free survival (PFS) and overall survival 
(OS). Added value from mutation status was evaluated using like-
lihood ratio (LR) tests. Classification and regression tree analysis 
aimed to identify homogeneous groups in terms of survival.
Results: Among the 522 patients, 87% were white, 32% were 
women, and 18% were never-smokers, with 65% presenting with 
adenocarcinoma. Biological data were available for 307 patients, 
showing 44 EGFR mutations (14%) and 42 KRAS (14%) muta-
tions. Median PFS was 2.4 months (interquartile range, 1.4–4.6) 
and median OS 5.6 months (interquartile range, 2.2–14.0). Factors 
independently associated with PFS were performance status 1 or 2 
to 3 (hazards ratio [HR] = 1.5, 95% confidence interval [CI] 1.1–1.9; 
and HR = 2.3, CI 1.7–3.1, respectively; p < 0.001); former or current 
smoker status (HR = 1.8, CI 1.4–2.4 and 2.0,CI 1.4–2.8, respectively; 
p < 0.001); nonadenocarcinoma histology (squamous cell: HR = 0.9 
CI 0.7–1.2]; others: HR = 1.6, 1.3–2.1; p < 0.001); at least two meta-
static sites (HR = 1.3, CI 1.1–1.6 and 1.6, CI 1.3–2.1, respectively; 
p < 0.001); prior taxane-based chemotherapy (HR = 1.3, CI 1.0–1.3, 
p = 0.01); non-white (HR = 0.7, CI 0.5–0.9, p = 0.009). Similar 
results were found for OS. In addition, EGFR and KRAS mutations 
were significantly associated with PFS (HR = 0.5, CI 0.3–0.7 and 
HR = 1.2, CI 0.8–1.8, respectively, versus no mutation; LR p = 0.001). 
In the OS model, adjusted HR was 0.7 (0.4–1.0) for EGFR mutation 
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/12/0710-1490
Impact of Systematic EGFR and KRAS Mutation Evaluation 
on Progression-Free Survival and Overall Survival  
in Patients with Advanced Non–Small-Cell Lung Cancer 
Treated by Erlotinib in a French Prospective Cohort 
(ERMETIC Project—Part 2)
 Jacques Cadranel, MD, PhD,*|| || || Audrey Mauguen, MSc,† Michele Faller, MD, PhD,‡|| || ||,  
Gérard Zalcman, MD, PhD,§|| || ||, Marie-Pierre Buisine, PharmD, PhD,||  Virginie Westeel, MD, PhD,¶ || || ||  
Elisabeth Longchampt, MD,# Marie Wislez, MD, PhD,*|| || || Bruno Coudert, MD,**|| || ||  
Catherine Daniel, MD,†‡|| || || Bruno Chetaille, MD,§§ Stephane Michiels, PhD,|| ||   
Helene Blons, MD, PhD,¶¶ Jerome Solassol, MD,## Florence De Fraipont, PharmD, PhD,***  
Pascal Foucher, MD,†††|| || || Thierry Urban, MD, PhD,‡‡‡|| || || Ludovic Lacroix, MD, PhD,§§§  
Virginie Poulot, LabTec,* Elisabeth Quoix, MD, PhD,†¶¶¶ Martine Antoine, MD,*|| || ||  
Guillaume Danton, LabTec,† Franck Morin, Ms, BSc,|| || || Christos Chouaid, MD, PhD,††|| || || and Jean-Pierre 
Pignon, MD, PhD,†|| || || on behalf of the ERMETIC collaborative group and the Intergroupe Francophone de 
Cancérologie Thoracique
*Service de Pneumologie—AH-HP Hôpital Tenon, Faculté de Médecine P&M 
Curie, université Paris 6 Paris, France; †Department of Biostatistics and 
Epidemiology, Institut de Cancérologie Gustave-Roussy, Villejuif, France; 
‡Laboratoire de Biologie Moléculaire, Hôpital de Hautepierre, Strasbourg; 
EA 4438, Université de Strasbourg, France; §CHU-CLCC, Caen, France; 
||Plateforme Régionale de Biologie Moléculaire des Cancers du C2RC, CHU-
CLCC de Lille, France; ¶CHU Besançon, France; #Hôpital Foch, Suresnes, 
France; **CLCC, Dijon, France; ††Service de Pneumologie, AP-HP Hôpital 
Saint-Antoine, Paris, France; ‡‡Institut Curie, Paris, France; §§Laboratoire 
d’Anatomie Pathologique, Institut Paoli-Calmettes, Marseille, France; ||||Breast 
Cancer Translational Research Unit, Institut Jules Bordet, Université libre 
de Bruxelles, Belgique; ¶¶AP-HP Hôpital Européen Georges Pompidou 
(HEGP), Paris, France; ##CHU Montpellier, France; ***CHU Grenoble, 
France; †††CHU Dijon, France; ‡‡‡Département de Pneumologie, CHU 
Angers, France; §§§Laboratoire, Institut Gustave-Roussy, Villejuif, France; 
||||||Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; 
and ¶¶¶Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg, France.
Jacques Cadranel and Audrey Mauguen were coprimary authors.
Disclosure: J. Cadranel and G. Zalcman have received fees for speaking 
and consulting from Astra-Zeneca and Roche; travel to the ASCO and 
International Association for the Study on Lung Cancer congresses was 
funded by Astra-Zeneca and Roche. The remaining authors have no con-
flicts of interest to declare.
Address for correspondence: Jacques Cadranel, Hôpital Tenon, Service de 
Pneumologie, 4 rue de Chine, F – 75970 Paris Cedex 20, France. E-mail: 
jacques.cadranel@tnn.aphp.fr
Journal of Thoracic Oncology
7
10
© 2012 by the International Association for the Study of Lung Cancer
1556-0864
JTO
202204
Evaluation of EGFR Mutation Status
Cadranel et al.
2012
October
00
00
10.1097/JTO.0b013e318265b2b5
Anjana
Original Article
ORIGINAL ARTICLE
1491Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012 Evaluation of EGFR Mutation Status
and 1.7 (1.1–2.4) for KRAS (LR p = 0.004). Classification and regres-
sion tree analysis revealed EGFR mutation to be the primary factor 
for identifying homogeneous patient subgroups in terms of PFS.
Conclusions: EGFR and KRAS status independently impacts 
outcomes in advanced non–small-cell lung cancer patients treated 
with EGFR-TKI. However, EGFR status impacts both PFS and OS 
whereas KRAS only impacts OS. These findings support the nation-
wide use of EGFR status for patient selection before EGFR-TKI 
therapy. The role of KRAS mutations remains to be elucidated.
Key Words: Non–small cell lung cancer, Tyrosine kinase inhibi-
tor treatment, Epidermal growth factor mutation, KRAS mutation, 
Prognostic factor, Prospective cohort.
(J Thorac Oncol. 2012;7: 1490–1502)
Since 2005, the use of epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlo-
tinib, has revolutionized the management of advanced non–
small-cell lung carcinoma (NSCLC). The BR21 trial showed 
erlotinib to be effective in advanced NSCLC patients unable 
to tolerate further treatment after receiving at least one plati-
num-based doublet,1 which was later confirmed by the Tarceva 
Lung Cancer Survival Treatment (TRUST) post-approval 
trial.2 In the Trial Evaluating REsponse and Survival versus 
Taxotere (INTEREST), gefitinib was shown to be equivalent 
to docetaxel as second-line therapy, but with improved quality 
of life.3
During the same period, several studies suggested that 
EGFR-TKI significantly benefited certain patient subgroups 
such as Asians, women, and never-smokers or former light-
smokers.4 Activating EGFR gene mutations in exons 19, 21, 
and occasionally, 18 seemed to confer sensitivity to EGFR-
TKI, whereas exon 20 mutations were associated with TKI 
resistance. Furthermore, KRAS-mutated tumors seemed 
resistant to EGFR-TKI,5 although KRAS mutations were 
responsible for only 20% of TKI treatment failures.6 Current 
research considers EGFR and KRAS mutations, found in 5% 
to 15% and 15% to 20% of unselected whites with lung ade-
nocarcinomas, respectively, to be mostly mutually exclusive.7
More recently, the Iressa Pan-Asia Study (IPASS) 
phase III trial compared gefitinib and carboplatin-paclitaxel 
as first-line therapies in Asian nonsmokers or former light-
smokers, demonstrating in this highly selected population 
that8: (1) only 60% of adenocarcinomas harbored EGFR 
mutations; (2) gefitinib was less effective in EGFR wild-type 
tumors; and (3) gefitinib was more effective than chemother-
apy in EGFR-mutated tumors. This last result was further 
confirmed by several trials involving gefitinib or erlotinib in 
EGFR-mutated populations,9–11 and was also shown to apply 
to whites in the European Tarceva versus Chemotherapy 
(EURTAC) trial.12
In 2005, the French National Cancer Institute (INCa) 
foresaw the importance of identifying EGFR-TKI predic-
tive markers, and consequently funded a nationwide multi-
center prospective project known as Evaluation of the EGFR 
Mutation status for the administration of EGFR-TKIs in non 
small cell lung Carcinoma (ERMETIC) involving 16 French 
centers. Its aims were to: (1) validate sequencing as screening 
for EGFR and KRAS molecular diagnosis in fixed paraffin-
embedded tissues; (2) select and rank clinical, pathological, 
and biological factors associated with prognosis in EGFR-
TKI–treated patients in a large unselected white prospective 
cohort; and (3) determine the most cost-effective strategy for 
prescribing EGFR-TKI, regardless of the use of EGFR bio-
markers. Our present study focuses on the second ERMETIC 
objective.
PATIENTS AND METHODS
Patients and Follow-Up
Between March 1, 2007 and April 1, 2008, the 
ERMETIC prospective and observational cohort included all 
patients with advanced NSCLC newly treated with EGFR-
TKI from 16 French centers after obtaining informed consent. 
Inclusion criteria were histologically or cytologically proven 
NSCLC, tumor assessment of less than 6 weeks, at least one 
evaluable lesion, and no ongoing chemotherapy or locore-
gional treatment. Previous EGFR-TKI treatment was not per-
mitted. The study was designed to demonstrate an increase 
from 10% to 36% in 3-month response rates in patients with 
wild-type and mutated tumors (odds ratio = 5). This hypothe-
sis was based on an odds ratio less optimistic (odds ratio = 10) 
than that reported by Han et al.13 Given a 10% EGFR mutation 
rate, a sample size of 297 patients was required to demon-
strate such an increase, with a type-I error of 1% and power 
of 85%. However, less than half of the patients were treated 
for 3 months, with tumor evaluation often carried out before 3 
months. As in recent studies, progression-free survival (PFS) 
was therefore taken as the primary endpoint and overall sur-
vival (OS) as the secondary.
TKI therapy was continued until disease progression, 
severe toxicity, or death. No predefined treatment was man-
datory in the case of disease progression or limiting toxicity 
under erlotinib. Follow-up occurred every 8 to 12 weeks until 
TKI treatment discontinuation, with dose modifications, TKI 
discontinuation, clinical results, and tumor response (World 
Health Organization criteria)14 recorded. After treatment dis-
continuation and until death, survival status was recorded 
every 3 months, with the cause of death noted.
Biological Assessment
Tumor samples were analyzed before TKI administra-
tion at initial diagnosis or during relapse, with the sample 
type (surgery, biopsy, or cytology), date, and percentage of 
tumor cells recorded. In the case of several samples, selection 
was based on the following order of preference: (1) samples 
with mutations, (2) samples with fewer nonamplifiable (NA) 
exons, (3) biopsy samples, and(4) samples closest to TKI 
initiation.
When the ERMETIC project began in 2005, limited 
information was available on the type and frequency of 
EGFR mutations, with DNA sequencing considered the 
most effective approach. On INCa’s request, all participating 
ERMETIC centers used direct or nested sequencing according 
to their own standard practices.15 In short, each center prepared 
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at least three 15-µm–thick sections from paraffin blocks for 
DNA extraction. Each center then sequenced EGFR (exons 
18, 19, 20, and 21) and KRAS (exon 2) genes. At least three 
polymerase chain reaction (PCR) amplification attempts were 
mandatory for each exon before the sample was considered 
not available. Mutations had to be detected in both strands 
and were confirmed by sequencing analysis using a second, 
independent PCR. Exon mutations were classified as wild 
type, mutated, or NA.
Statistical Issues
Endpoint definitions 
PFS was defined as the time between TKI initiation and 
progression (even if investigator decision was to continue 
erlotinib) or all-cause death. Patients alive without progres-
sion were censored at the last follow-up. OS was defined as 
the time between TKI initiation and all-cause death, with 
patients alive being censored at the last follow-up.
Impact of clinical and biological characteristics  
on survival
Survival rates were estimated using the Kaplan–Meier 
method, with 95% confidence intervals (CI) calculated with 
Rothman’s method.16 Median follow-up was estimated using 
the reversed Kaplan–Meier method.17 Impact on survival was 
quantified using Cox models and hazards ratios (HR) with 
95% CI. Variables with a p value less than 0.25 in univariate 
analysis were introduced into multivariate analyses. A back-
ward selection was undertaken, with the final model including 
variables with a p value less than 0.05.
A nested likelihood ratio (LR) test was used to verify 
the independent impact of mutations. Discrimination of the 
proposed models was estimated using the c-index,18 which 
varied from 0.5 (random concordance) to 1 (perfect concor-
dance), using the R package Survival. A bootstrap resampling 
procedure (1000 resamples) was used to correct the c-index 
for overoptimism caused by possible overfitting and estimate 
a 95% bootstrap percentile CI. The number of times a variable 
was selected in each bootstrap resample was calculated.
Clinical model
Predefined clinical variables were: age, sex, ethnic 
origin, smoking status, performance status (PS), histology, 
initial disease stage, number of metastatic sites at TKI initia-
tion, presence of brain, bone, or lung metastases, surgery or 
radiotherapy at the primary site, previous chemotherapy, and 
indication for TKI (Table 1). Prognostic values were estimated 
based on the entire population (n = 522 patients, Fig. 1).
Biological Model
For the biological model, only mutated and wild-type 
cases were considered, with NA excluded. EGFR mutation 
was defined as exon 18, 19, or 21 mutations, with exon 20 not 
considered because of its low frequency (n = 3) and associa-
tion with TKI resistance. If exons 19 or 21 were NA and no 
mutation was found on the other exons, the tumor was consid-
ered not available. Otherwise the tumor was considered EGFR 
wild-type. A KRAS mutation was defined as a mutation found 
TABLE 1. Patient Characteristics (N = 522)
Characteristics n %
Age category (yrs)
 <60 201 39
 60–69 172 33
 ≤70 149 28
Female sex 168 32
Ethnic origin (2 MD)
 Two European parents 453 87
 At least one Asian parent 5 1
 Othera 62 12
Smoking status (4 MD)
 Current smoker 75 14
 Former smoker 349 68
 Nonsmokerb 94 18
Performance status (45 MD)
 0 87 18
 1 244 51
 2 115 24
 3 31 6
Histology (5 MD)
 Adenocarcinoma 335 65
 Squamous cell 94 18
 Other 88 17
Initial disease stage (2 MD)
 Stage I–II–IIIA 103 20
 Stage IIIB 61 12
 Stage IV 356 68
Number of metastatic sites at TKI initiation (10 MD)
 0 46 9
 1 182 35
 2 146 29
 3–6 138 27
Localization of metastasis at TKI initiation
 Lung (6 MD) 244 47
 Bone (3 MD) 205 39
 Brain (2 MD) 143 27
Indication of prescription
 First-linec 55 11
 Second-line 238 46
 Third-line or more 229 44
Previous chemotherapy received (all lines)d 478 92
 Platinum 447 94
 Taxane 264 55
 Gemcitabine 215 45
 Pemetrexed 139 30
 Other 54 11
aOther: North Africa (n = 23), Near- and Middle-East (n = 6), one European parent 
(n = 6), Sub-Saharan Africa (n = 4), Madagascar (n = 1), Africa plus Europe plus Asia 
(n = 1), not specified (n = 21).
bNonsmoker defined as smoking <100 cigarettes in a lifetime.
cAmong the 55 patients receiving first-line treatment, 50 were included in a clinical 
trial.
dFor chemotherapy type, the denominator for percentages is for patients who 
received chemotherapy (n = 478).
MD, Missing data; TKI, tyrosine kinase inhibitor.
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on exon 2. If the result on exon 2 was wild type, the status 
was considered KRAS wild type. Finally, as EGFR and KRAS 
mutations were considered mutually exclusive, if a tumor was 
KRAS-mutated but with unavailable EGFR status, the tumor 
was considered EGFR wild type (n = 7). Conversely, if a 
tumor was EGFR-mutated but with unavailable KRAS status, 
the tumor was considered KRAS wild type (n = 4). Data relat-
ing to mutations were classified into three groups: no muta-
tion (EGFR and KRAS wild type), EGFR mutation, or KRAS 
mutation. The impact of biological variables on survival was 
assessed in the 307 patients with known EGFR and KRAS 
mutational status (Fig. 1). Characteristics of clinical and bio-
logical populations were compared using χ2 tests.
Recursive Partitioning and Regression Tree
Regression trees were built using the classification and 
regression tree (CART) method on the biological population,19 
which represented the analysis visually. On the basis of clini-
cal or biological characteristics, patients were recursively par-
titioned into two groups as homogeneous as possible in terms 
of outcome. Groups of fewer than 30 patients (10% of the total 
sample) were not permitted. The regression tree was built on 
our previous Cox proportional hazard model selection using 
the rpart library,20 SAS software, version 9.1 (SAS Institute, 
Cary, NC), was used for the other analyses.
Role of Funding
The sponsor of the study (French Ministry of Health) 
had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all data and was responsible for the 
decision to submit for publication.
RESULTS
In total, 530 patients were included in the ERMETIC 
cohort, with eight subsequently excluded from analysis 
(Fig. 1). Final analysis was performed on 522 patients, with 
a median follow-up of 22 months (interquartile range [IQR] 
19–25 months). The cutoff date of analysis was October 1, 
2009.
Patients Characteristics, Treatments, 
and EGFR/KRAS Status
Patient characteristics are given in Table 1. Median 
patient age was 63 years (IQR, 56–71 years), with 32% of the 
patients being women. In total, 94 patients (18%) had never 
smoked, with adenocarcinoma being the most frequent histol-
ogy (335 patients, 65%). At TKI initiation, 91% of the patients 
(466 of 512) exhibited metastatic disease. TKI treatment was 
erlotinib in all patients, with a daily dose of 150 mg for 98%. 
As erlotinib was not authorized in France as first-line therapy 
at the time of study initiation, 90% of the patients were under-
going second- or third-line treatment or more.
Tissue samples were available for sequencing in 420 of 
522 eligible patients (80%), with DNA being NA in 55 samples, 
and EGFR or KRAS sequencing results noninterpretable in 58 
other samples. EGFR and KRAS sequencing was consequently 
performed on 307 samples (70%) taken from 214 biopsies, 69 
530 patients included in the cohort 
-  Five patients excluded 
- two previously treated with EGFR-TKI 
- three due to miscellaneous reasons 
(erroneous diagnosis, consent withdrawal, treatment
by another EGFR-TKI) 
-  Three patients without baseline assessment and 
follow-up
522 patients analyzed 
in the clinical model   
(434 deaths; 481 events) 
- 102 patients (20%) without tissue samples for 
sequencing 
- 55 patients (11%) with non-amplified DNA 
samples  
- 58 patients (11%) with missing results for EGFR 
(exons 18, 19, and 21) or KRAS status 
307 patients analyzed 
in the biological model   
(258 deaths; 281 events) 
FIGURE 1.  Flow chart. EGFR-TKI, 
epidermal growth factor tyrosine 
kinase inhibitor.
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surgeries (22%), and 22 cytologies (7%), plus two samples 
(1%) of unspecified origin. The median proportion of tumor 
cells from samples was 50% (IQR 30%–70% for 249 samples).
As regards EGFR mutations, three were found on exon 
18 (276 wild type and 28 NA), 27 on exon 19 (273 wild type 
and 7 NA), and 16 on exon 21 (285 wild type and 6 NA). 
KRAS mutations were found on 42 samples (261 wild type 
and 4 NA). The mutation rate was 14% for EGFR (44 of 
307 patients), 14% for KRAS (42 of 307), and 72% for wild 
type (221 of 307), with no patient presenting both EGFR and 
KRAS mutations.
The proportion of never-smokers was higher in patients 
with EGFR mutations (21 of 44, 48%) than in those with wild 
type (37 of 221, 17%), whereas patients with KRAS muta-
tions were all smokers (p < 0.001). In addition, the proportion 
of adenocarcinoma was significantly higher in patients with 
mutations compared with those with no mutations (p = 0.02). 
No association was found between mutations and sex or any 
other clinical factors (Table 2).
PFS and OS
In the overall population, 434 deaths and 481 events 
occurred during follow-up. Median PFS was 2.4 months 
(IQR, 1.4–4.5), with the 6-month PFS rate being 21% (95% 
CI, 17–24) (Fig. 2A). Median PFS was 3.4 (IQR, 1.7–10.4), 
2.4 (IQR, 1.3–5.0), and 2.3 (IQR, 1.4–3.6) months in patients 
receiving erlotinib as first-, second-, and third-line therapy or 
more, respectively. Median OS was 5.6 months (IQR, 2.3–14.6 
months), with the 1-year OS rate being 31% (95% CI, 27–35) 
(Fig. 2A). When analyzed by therapy line, median OS was 8.2 
(IQR, 2.6–not reached), 6.7 (IQR, 2.4–17.8), and 4.5 (IQR, 2.1–
12.1) months, respectively. The main cause of death was cancer 
(n = 384), with other deaths related to intercurrent disease (n = 
14 for pulmonary and n = 4 for cardiac), chemotherapy toxicity 
(n = 2), other causes (n = 15), and nonspecified (n = 15).
Clinical Prognostic Models
In multivariate analyses (Table 3), the clinical factors 
significantly associated with a higher progression risk were 
TABLE 2. Association between Mutation Status and Clinical Factors in the Biological Population (N = 307)
Clinical Factors 
No Mutation 
n (%)
EGFR Mutation 
n (%)
KRAS Mutation 
n (%) Wald p
Total 221 44 42
Sex
 Female 70 (32) 17 (39) 13 (31) 0.65
 Male 151 (68) 27 (61) 29 (69)
Geographical origin (1 MD)
 Two European parents 189 (86) 37 (84) 38 (90) 0.66
 Others 31 (14) 7 (16) 4 (10)
Smoking status (3 MD)
 Never 37 (17) 21 (48) 0 (0) <0.001
 Former 146 (67) 19 (43) 35 (83)
 Current 35 (16) 4 (9) 7 (17)
Performance status
 0 30 (14) 7 (16) 9 (21) 0.86
 1 112 (51) 22 (50) 21 (50)
 2 or 3 64 (29) 11 (25) 10 (24)
 Missing 15 (7) 4 (9) 2 (5)
Histology (3 MD)
 Adenocarcinoma 127 (58) 32 (74) 31 (74) 0.02
 Squamous cell 46 (21) 4 (9) 1 (2)
 Others 46 (21) 7 (16) 10 (24)
Number of metastatic sites (5 MD)
 0 or 1 94 (43) 22 (52) 18 (44) 0.62
 2 64 (29) 13 (31) 11 (27)
 3 or more 61 (28) 7 (17) 12 (29)
Lung metastasis (3 MD)
 No 122 (55) 23 (53) 19 (46) 0.56
 Yes 98 (45) 20 (47) 22 (54)
Previous chemotherapy with taxane
 No 106 (48) 25 (57) 19 (45) 0.49
 Yes 115 (52) 19 (43) 23 (55)
MD, Missing data. 
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being former or current smoker, PS 1 or higher, histology other 
than adenocarcinoma, more than one metastatic site, and prior 
taxane-based chemotherapy. Having at least one non-white 
parent was significantly associated with a lower risk of progression. 
The same factors (Table 3) were associated with OS, except that 
lung metastasis was significantly associated with OS, whereas 
prior taxane-based chemotherapy was not. The selection steps 
are shown in the Online Supplement Table 1 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A328).
Clinical and Biological Prognostic Model
Characteristics of patients (n = 307) included in the 
biological model were similar to those of patients (n = 215) 
who did not have mutational analysis results, except with 
regard to histology, with fewer cases of adenocarcinoma and 
squamous cell carcinoma in the biological population (p = 
0.03). In addition, PFS and OS were similar in both popula-
tions (Fig. 2A and B).
In the biological population, median PFS was 8.4 
(IQR, 2.6–21.2), 2.3 (IQR, 1.3–3.6), and 1.9 (IQR, 0.9–3.6) 
months for patients with EGFR mutation, wild-type, and 
KRAS mutation, respectively (Fig. 3A). The corresponding 
1-year survival rates were 43% (95% CI, 30–58), 10% (95% 
CI, 6–14), and 12% (95% CI, 5–25), respectively. Median 
OS was 14.4 (IQR, 3.5–23.3), 5.3 (IQR, 2.1–12.4), and 4.1 
(IQR, 1.7–7.9) months for patients with EGFR mutation, 
wild-type, and KRAS mutation, respectively (Fig. 3B). 
The corresponding 1-year OS rates were 57% (95% CI, 
42–70), 27% (95% CI, 21–33), and 19% (95% CI, 10–33), 
respectively.
The final clinical model, including the aforementioned 
factors, was run on the biological population (Table 3). When 
considering the clinical and biological populations, the same 
factors were significantly associated with PFS, except with 
regard to taxane-based chemotherapy, and with OS, except 
with regard to histological type. After adjusting for the clini-
cal model, mutation status was significantly associated with 
both PFS and OS (Table 4). EGFR mutations significantly 
decreased the risk of progression or death by 50% (Wald test, 
p = 0.001), while adding independent information to the clini-
cal model (LR test, Δχ² = 15.6, df = 2, and p = 0.0004). KRAS 
mutations significantly increased the risk of death by 70%, 
whereas EGFR mutations decreased this risk by 30% (Wald 
test, p = 0.004), with the mutation adding information to the 
clinical model (LR test, Δχ² = 10.8, df = 2, p = 0.004). The 
c-index of the PFS model slightly increased from 0.620 (95% 
CI 0.594–0.665) to 0.633 (95% CI 0.606–0.678) when muta-
tion status was incorporated into the model (Supplementary 
Table 2, Supplementary Digital Content 1, http://links.lww.
com/JTO/A328).
 This means that patient rank in terms of survival pre-
dicted by the model was concordant with that observed in 63% 
of all patient pairs tested. Similar results were found for OS, 
with the c-index increasing from 0.648 (95% CI 0.624–0.690) 
to 0.654 (95% CI 0630–0.695).
The bootstrap resampling of the Cox proportional haz-
ards model showed that PS, mutations, histology, and initial 
number of metastatic sites were selected in more than 80% 
of the models. Although not retained in our final model, indi-
cation of prescription was selected in 54% of the samples, 
whereas ethnic origin and smoking status were selected in 
45% and 41% of the samples, respectively, when mutations 
were considered (Supplementary Table 3, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A328). 
For the OS model, PS was selected in all samples and 
mutations in 82%.
Recursive Partitioning and Regression Trees
The primary predictor of PFS was EGFR mutation 
(Fig. 4A), which isolated a group of 44 patients with the best 
PFS. Among EGFR wild-type patients, PS followed by the 
initial number of metastatic sites best defined homogeneous 
patient groups in terms of PFS. Four groups were accordingly 
identified, presenting significantly different survival rates 
(log-rank test: p < 0.0001) (Fig. 4B). Median PFS of the four 
groups was 8.4 (IQR, 2.6–21.2), 2.9 (IQR, 2.1–11.3), 2.5 
(IQR, 1.3–4.7), and 1.9 (IQR, 1.0–2.9) months. The c-index 
corresponding to the concordance ability of these four groups 
was 0.619 (95% CI 0.583–0.653) (Supplementary Table 2, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A328).
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FIGURE 2. Progression-free survival and overall survival 
curves for A, the clinical population (n = 522), and (B)  
biological population (n = 307). m, months.
1496 Copyright © 2012 by the International Association for the Study of Lung Cancer
Cadranel et al. Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012
The primary predictor for OS was PS (Fig. 5A), followed 
by EGFR mutation status and initial number of metastatic 
sites. Five groups were accordingly identified, presenting sig-
nificantly different OS (log-rank test: p < 0.0001) (Fig. 5B), 
with median OS of 18.6 (IQR, 8.5–28.4), 8.8 (IQR, 3.5–17.4), 
4.7 (IQR, 1.8–9.7), 3.8 (IQR, 1.6–10.1), and 2.3 (IQR, 1.1–
4.0) months. The corresponding c-index was 0.645 (95% CI, 
0.611–0.679).
DISCUSSION
Recent studies have highlighted the need to implement 
a reliable program so as to identify EGFR mutations in the 
general population,21 as NSCLC response rates to EGFR-TKI 
therapy in terms of PFS and quality of life were shown to be 
higher in patients with EGFR-activating mutations, who also 
exhibited a better prognosis.8–12 In contrast, KRAS mutations 
were inconstantly reported to be negative predictors of ben-
efit from EGFR-TKI therapy.5 In addition, recent data have 
suggested that EGFR and KRAS mutations were mutually 
exclusive, reflecting different mechanisms of carcinogenesis.4 
Although several consensus articles on EGFR testing have been 
published22,23 before our project, no population-based studies 
had investigated the role and feasibility of EGFR mutation 
screening in determining NSCLC therapy. In anticipation, the 
ERMETIC project was initiated in 2005 to identify biomark-
ers associated with a better outcome after EGFR-TKI therapy 
and to implement their use in a prospective, unselected white 
cohort treated by TKI. This project validated a standardized 
technique based on fixed paraffin-embedded tissues after an 
initial quality-assurance phase conducted among 16 centers,15 
with a separate publication demonstrating the cost-effective-
ness of this screening test.24 The current report confirmed the 
TABLE 3. Clinical Multivariate Models for Progression-Free Survival and Overall Survival in the Clinical and Biological 
Populations (n = 522 and n = 307 Patients; 502 and 295 in Multivariate Models)
Progression-Free Survival Overall Survival
Clinical Populationa Biological Populationb Clinical Populationc Biological Populationd
HR [95% CI] p HR [95% CI] p HR [95% CI] P HR [95% CI] p
Geographical origin     
 Two European parents 1e 0.009 1e 0.01 1e 0.004 1e 0.005
 Others 0.7 [0.5–0.9] 0.6 [0·4–0·9] 0.6 [0.5–0.9] 0.6 [0.4–0.8]
Smoking status
 Never 1e <0.001 1e 0.002 1e <0.001 1e 0.007
 Former 1.8 [1.4–2.4] 1.8 [1.3–2.5] 1.5 [1.1–2.0] 1.5 [1.1–2.2]
 Current 2.0 [1.4–2.8] 1.8 [1.2–2.9] 2.1 [1.5–3.0] 2.1 [1.3–3.3]
Performance status
 0 1e <0.001 1e <0.001 1e <0.001 1e <0.001
 1 1.5 [1.1–1.9] 1.7 [1.2–2.5] 1.6 [1.2–2.2] 1.5 [1.0–2.3]
 2 or 3 2.3 [1.7–3.1] 2.5 [1.6–3.7] 3.3[2.3–4.5] 3.0 [1.9–4.6]
 Missing 1.7 [1.2–2.6] 1.9 [1.0–3.4] 1.8 [1.2–2.8] 1.0 [0.54–1.9]
Histology (5 MD)
 Adenocarcinoma 1e <0.001 1e 0.003 1e 0.02 1e 0.26
 Squamous cell 0.9 [0.7–1·2] 0·9 [0·6–1·2] 1.2 [0.9–1.6] 1.2 [0.9–1.8]
 Others 1.6 [1.3–2.1] 1·6 [1·2–2·2] 1.5 [1.1–1.9] 1.3 [0.9–1.8]
Initial number of metastatic 
sites (10 MD)
 0 or 1 1e <0.001 1e 0.003 1e <0·001 1e <0.001
 2 1.3 [1.1–1.6] 1.4 [1.0–1.9] 1.5 [1.2–1.9] 1.4 [1.0–1.9]
 3 or more 1.6 [1.3–2.0] 1.7 [1.2–2.3] 2.2 [1.7–2.8] 2.1 [1.5–3.0]
Previous chemotherapy with 
taxane
 No 1e 0.01 1e 0.09 — — — —
 Yes 1.3 [1.1–1.5] 1.2 [1.0–1.6] — — — —
Lung metastasis (6 MD)
 No — — — — 1e 0.002 1e 0.007
 Yes — — — — 0.7 [0.6–0.8] 0.69 [0.5–0.9]
aFive hundred and twenty-two patients.
bThree hundred and seven patients.
cFive hundred and two patients.
d295 patients.
eReference classes.
HR, hazards ratio; CI, confidence interval; MD, missing data in the clinical population. 
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feasibility in real time of this screening test on a large patient 
population. In the regression tree analyses, EGFR mutations, 
but not KRAS, were shown to be the primary predictor of PFS 
in TKI therapy followed by PS and metastatic disease. In con-
trast, histology and smoking status had no relevant impact.
The majority of our population was white, undergoing 
second- or third-line therapy. Overall, the results in terms 
of PFS, OS, and 1-year OS were in line with those previ-
ously reported by the BR21 and INTEREST trials.1,3 In the 
TRUST population-based cohort, PFS was 3.25 months 
(95% CI, 3.06–3.42), OS, 7.9 months (95% CI, 7.59–8.28) 
and 1-year OS, 37.7% (95% CI, 36.5–38.9). This popula-
tion, however, comprised 20% Asians and 30% nonsmok-
ers.2 Expectedly, factors such as PS, tobacco consumption, 
histology other than adenocarcinoma, and metastatic spread 
at TKI therapy initiation were better predictors of PFS and 
OS than initial TNM.
Tissue samples were available at diagnosis for 80% of eli-
gible patients, which was far superior to levels previously reported 
in prospective trials (<36%).25 In France, a significant effort has 
been made by INCa to implement a national network of clini-
cians, pathologists, and molecular biologists focused on EGFR 
mutations.21 Our sample recovery rate may be further improved 
by increasing the number of biopsies taken at diagnosis.23 Overall, 
70% of the samples were obtained via bronchial or computed 
tomography guided transparietal biopsies. In 75% of the cases, the 
samples comprised at least 30% tumor cells, meaning that a micro-
dissection technique was usually not necessary.23 In 20% of the 
cases, because of the poor quality of extractable DNA, PCR ampli-
fication of at least one exon was impossible, whereas in 20% of 
further samples, PCR amplification was not possible for all exons. 
Alternative techniques, yielding better results,23 are currently being 
investigated in the upcoming ERMETIC II project.
In our cohort, the 14% EGFR mutation rate was slightly 
higher than expected in an unselected white population 
(<10%), whereas the 14% KRAS mutation rate was lower 
(15%–25%).5,7 No exotic EGFR mutations were detected, and 
more than 90% of EGFR mutations were exon 19 deletions 
(n = 27, 61%) or point mutations of exon 21 (n = 16, 33%). As 
most patients (89%) had already received first-line therapy, a 
certain enrichment regarding histology (65% adenocarcinoma), 
sex (32% female), tobacco consumption (18% never-smokers), 
and prognosis was likely. Interestingly, clinical features such as 
sex or adenocarcinoma histology were not able to differentiate 
patients with EGFR mutations, KRAS mutations, or wild-type 
status, whereas tobacco use concerned all KRAS mutation 
patients, and 48% of EGFR-mutated patients were never-
smokers. These data are in line with the IPASS trial, in which 
40% of the selected patients who were likely to present a 
mutation did not.8 Another advantage of the ERMETIC study 
was its inclusion of smokers, because the omission of smokers 
or former smokers from our cohort would have meant missing 
52% of EGFR-mutated patients, as recently reported.26
Activating EGFR mutations resulted in significantly pro-
longed PFS (8.4 versus 2.3 months with no mutation), though 
inferior to prior prospective phase III studies with erlotinib (9.7–
13.1 months)11,12 or gefitinib (9.2–10.8 months).8–10 This differ-
ence may be explained by our mutation population being almost 
entirely white, 61% men, 52% smokers, 25% presenting PS of 2 
or more, and 89% having received one or more therapeutic lines, 
all factors known to decrease PFS. In multivariate analyses, the 
probability of disease progression under erlotinib therapy was 
reduced by 50% in EGFR-mutated patients. In the biological 
population, smoking status was not associated with PFS, thus 
confirming the relevance of biological markers in the decision-
making process. Surprisingly, the median PFS of a Spanish 
cohort (14 months; 95% CI, 7.7–11.3)27 was markedly superior 
to that of the French ERMETIC cohort, as was that obtained in 
the EURTAC trial12 (9.7 months). However, the Spanish cohort 
was also probably more selected. It included a higher proportion 
of women (69.7% versus 39%) and never-smokers (66% versus 
48%) among mutant patients, with PS not reported and 50% of 
patients undergoing first-line therapy, with third-line therapy not 
defined. Finally, the EGFR mutation rate was 16.6%, which is 
higher than expected in an unselected white population.
Our study confirmed that KRAS mutations had little 
impact on PFS,5 which seems to be in contradiction with 
the nonresponse of KRAS-mutated patients to TKI therapy 
reported in the scientific literature. The reason for this may be 
that KRAS mutations are responsible for only 20% of primary 
TKI-resistance mechanisms.6 Indeed, in EGFR and KRAS 
wild-type patients, other biological markers, such as loss of 
phosphatase and TENsin homolog, v-raf murine sarcoma 
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FIGURE 3. A, Progression-free survival and (B) overall survival 
curves by mutation status. m, months.
1498 Copyright © 2012 by the International Association for the Study of Lung Cancer
Cadranel et al. Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012
viral oncogee homolog B1 mutations, and alterations of c-met 
or insulin-like growth factor receptor-1 pathways, may be 
responsible for primary TKI-resistance, but were not assessed 
in our study.25
As regards statistical analysis, factors associated with 
better outcome were assessed using two complementary 
methods. The Cox model identified relevant factors, quan-
tified their association with patient outcome, and revealed 
an independent contribution of the mutations using the LR 
test, whereas the CART method provided a comprehensive 
illustration of these results. Expectedly, the EGFR mutation 
(HR = 0.67) proved to be an independent factor of OS, but 
unexpectedly, KRAS mutation did as well (HR = 1.70). 
Although KRAS mutations are associated with smoking status 
and smoking is a poor prognostic factor, smoking status could 
not be considered as a confounding variable in our results, as 
it was included in the multivariable analyses.
Concordance values of our models were in line with 
cancer study findings.28 The rise in the c-index brought upon 
by the mutation was small, but sustained through the bootstrap 
correction. Moreover, the CART analysis showed that EGFR 
mutation was clearly the primary factor for differentiating 
patients with respect to risk of progression or death, whereas 
PS played a relevant role only in patients without the EGFR 
mutation. The strength of the association between mutation 
and PFS was emphasized by the bootstrap validation, suggest-
ing that these results, observed on a prospective cohort, could 
hold for a new population. However, validation of these results 
in an independent cohort is still necessary. Finally, because 
of the lack of a randomized control group, it was impossible 
TABLE 4. Final Prognostic Models for Progression-Free and Overall Survival on the Biological Population (n = 307 patients; 295 
in multivariate models)
Final Models
Progression-Free Survival Overall Survival
HR [95% CI] p HR [95% CI] p
Mutation status
 No mutation 1a 0.001 1a 0.004
 EGFR mutation 0.5 [0.3–0.7] 0.7 [0.4–1.0]
 KRAS mutation 1.2 [0.8–1.8]  1.7 [1.1–2.4]  
Geographical origin   
 Two European parents 1a 0.02 1a 0.004
 Others 0.6 [0.4–0.9]  0.5 [0.4–0.8]
Smoking status
 Never 1a 0.24 1a 0.09
 Former 1.4 [1.0–2.0] 1.2 [0.8–1.8]
 Current 1.4 [0.9–2.2] 1.7 [1.0–2.7]
Performance status
 0 1a <0.001 1a <0.001
 1 1.8 [1.2–2.7] 1.7 [1.1–25]
 2 or 3 2.6 [1.7–4.0] 3.4 [2.1–5.3]
 Missing 2.0 [1.1–3.7] 1.1 [0.6–2.2]
Histology (5 MD)   
 Adenocarcinoma 1a 0.003 1a 0.18
 Squamous cell 0.8 [0.6–1.2]  1.3 [0.9–1.9]
 Others 1.6 [1.2–2.2]  1.3 [0.9–1.8]
Initial number of metastatic sites (10 MD)
 0 or 1 1a 0.004 1a <0.001
 2 1.4 [1.1–1.9] 1.4 [1.1–1. 9]
 3 or more 1.7 [1.2–2.3] 2.1 [1.5–3.0]
Previous chemotherapy with taxane
 No 1a 0.11 — —
 Yes 1.2 [1.0–1.6]  — —
Lung metastasis (6 MD)
 No — — 1a 0.007
 Yes — — 0.7 [0.5–0.9]
p Values are from the Wald statistic.
aReference classes.
HR, hazards ratio; CI, confidence interval; MD, missing data.
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to differentiate between the predictive and prognostic roles of 
EGFR mutation. In terms of OS, the role of EGFR mutation 
was only relevant for patients presenting a PS of 1 or lesser, 
suggesting that only this patient population would benefit 
from another treatment line in the case of progression under 
second- or third-line TKI therapy.
CONCLUSIONS
In this first exhaustive cohort study on EGFR and KRAS 
mutations in an unselected white population undergoing 
second- or third-line EGFR-TKI, tissue sampling at diagno-
sis was feasible in 80% of the cases. However, improvements 
in molecular analysis are still required, as 20% of samples 
could not be analyzed. The positive effect of activating EGFR 
mutations on OS, along with the negative effect of KRAS muta-
tion, was confirmed in this large white population, and the 
French regional network for detecting mutations has shown its 
cost-effectiveness.
Nevertheless, we cannot firmly conclude that KRAS 
mutational status should or should not be included in the 
FIGURE 4. A, Regression tree for PFS 
and (B) PFS curves corresponding to 
the four final groups of the regression 
tree. PFS, progression-free survival; PS, 
performance status; HR, hazards ratio; 
m, months.
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decision to offer erlotinib therapy to patients. However, 
there was an accumulation of data suggesting that patients 
with KRAS-mutated tumors did not respond to EGFR ther-
apy, although KRAS mutations accounted for only 20% of 
molecular alterations leading to such resistance.5,6 This low 
proportion of KRAS resistance mechanisms characterized in 
our study and previous ones may explain why we and others 
have failed to demonstrate any difference in survival between 
EGFR-TKI-treated patients with and without KRAS-mutated 
tumors (but all with EGFR wild-type gene).
Finally, we have clearly shown that biological mark-
ers in relation to EGFR status were more relevant than 
patient characteristics in differentiating the therapeutic 
impact of TKI. Given this, our results are consistent with 
FIGURE 5. A, Regression tree for 
OS and (B) OS curves corresponding 
to the five final groups of the regres-
sion tree. PS, performance status; HR, 
hazards ratio; OS, overall survival; m, 
months.
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the recommendations for EGFR analysis as a standard of 
care for first-line EGFR therapy in patients with advanced 
NSCLC (especially in the case of adenocarcinoma histol-
ogy).22,23 Furthermore, our study has provided more evidence 
that EGFR mutation status evaluation may impact patient 
outcomes in second- or third-line settings. This is important 
so as not to delay the initiation of EGFR-TKI in patients with 
EGFR-activating mutation.
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